0001022079-21-000146.txt : 20211201 0001022079-21-000146.hdr.sgml : 20211201 20211201163423 ACCESSION NUMBER: 0001022079-21-000146 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211129 FILED AS OF DATE: 20211201 DATE AS OF CHANGE: 20211201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doherty Catherine T. CENTRAL INDEX KEY: 0001520897 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 211463461 MAIL ADDRESS: STREET 1: C/O QUEST DIAGNOSTICS STREET 2: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 4 1 wf-form4_163839444899069.xml FORM 4 X0306 4 2021-11-29 0 0001022079 QUEST DIAGNOSTICS INC DGX 0001520897 Doherty Catherine T. 500 PLAZA DRIVE SECAUCUS NJ 07094 0 1 0 0 SVP, Group Exec. Clin. Fran. Common Stock 2021-11-29 4 M 0 37565 95.795 A 106294 D Common Stock 2021-11-29 4 S 0 300 153.383 D 105994 D Common Stock 2021-11-29 4 S 0 3250 154.792 D 102744 D Common Stock 2021-11-29 4 S 0 3532 155.774 D 99212 D Common Stock 2021-11-29 4 S 0 15908 156.855 D 83304 D Common Stock 2021-11-29 4 S 0 14575 157.533 D 68729 D Common Stock 4136 I 401(k)/SDCP Non-Qualifed Stock Option (right to buy) 95.795 2021-11-29 4 M 0 37565 95.795 D 2027-02-21 Common Stock 37565.0 0 D This exercise and sales reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 29, 2021. This transaction was executed in multiple trades at prices ranging from $153.21 to $153.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $154.21 to $155.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $155.26 to $156.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $156.27 to $157.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $157.27 to $158.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. The options vested in three annual installments beginning with the first on February 21, 2018, the second on February 21, 2019 and the final on February 21, 2020. /s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Catherine T. Doherty 2021-12-01